<--- Back to Details
First PageDocument Content
Immunotherapy / Prostate cancer / Leukapheresis / Neuvenge / Medicine / Dendreon / Immunology
Immunotherapy
Prostate cancer
Leukapheresis
Neuvenge
Medicine
Dendreon
Immunology

HIGHLIGHTS OF PRESCRIBING INFORMATION

Add to Reading List

Source URL: www.fda.gov

Download Document from Source Website

File Size: 236,92 KB

Share Document on Facebook

Similar Documents

Prostate cancer / RTT / Medical physics / Cancer vaccines / Histopathology / Dendreon / Treatment of cancer / Prostate / Sipuleucel-T / Radiation therapy / Cancer / Oncology

About Advanced Prostate Cancer Treatment Options Resources Prostate Cancer Navigator

DocID: 1oTjG - View Document

Biology / Debiopharm / Liposome / Biotechnology / Pharmacology / Dendreon / Cancer vaccine

BIOTECH’S MOST RESPECTED NEWS SOURCE FOR MORE THAN 20 YEARS THURSDAY MARCH 15, 2012 VOLUME 23 , NO. 51

DocID: 19ZND - View Document

Biotechnology / Cell biology / Emerging technologies / Childbirth / Cell therapy / Cord blood bank / Dendreon / Cord blood / Stem cell / Biology / Medicine / Stem cells

Developing GMP IPS Lines - Identifying and Eliminating Roadblocks Mahendra Rao, M.D., Ph.D., (former) Director NIH CRM, Laboratory of Stem Cell Biology Chief, The Path to Personalized Medicine

DocID: 14kRG - View Document

Dendreon / Medicare / Medicine / Prostate cancer / Medicaid / Health / Government / Health economics / Healthcare reform in the United States / Federal assistance in the United States / Presidency of Lyndon B. Johnson

Medicare to pay for $93,000 prostate cancer drug

DocID: Rsxd - View Document

Boehringer Ingelheim / Duloxetine / Eli / Lilly / Chemistry / Dendreon / Eli Lilly and Company / Indiana / Pharmaceutical industry

seen on the most sites For the second straight year, Janssen’s oral anticoagulant Xarelto was the most widely advertised branded drug on sites tracked by Kantar’s Evaliant tool (last year it tied for the top spot wit

DocID: O0pR - View Document